GlycoMimetics to Present Preclinical Cancer Results at Society for Immunotherapy of Cancer Meeting
November 08 2016 - 9:00AM
Business Wire
- Data illustrate potential for synergy between drug candidate
GMI-1359 and PD-L1 antagonists when used in combination to treat
solid tumors
GlycoMimetics, Inc. (NASDAQ: GLYC) today announced that data
showing enhanced effectiveness of an antibody antagonist to a key
cancer regulatory ligand, PD-L1, in combination with its drug
candidate GMI-1359 will be presented at the Society for
Immunotherapy of Cancer (SITC) Annual Meeting & Associated
Programs. The SITC meeting will take place November 9 to 13 in
National Harbor, Maryland.
The poster presentation reviews the results of pre-clinical
research on the company’s dual E-selectin/CXCR4 antagonist
GMI-1359. The data presented will show that GMI-1359 in combination
with an antibody against the cancer regulatory programmed death
receptor ligand, PD-L1, shortened time to complete tumor
regressions in an animal model of colon cancer. The combination
therapy also selectively reduced regulatory T cells (a class of
lymphocytes that suppress immune responses) in the tumor, and
created a more favorable immune-mediated anti-tumor
environment.
“We are very pleased to announce these results, which show the
possible synergy between GMI-1359 and PD-L1 antagonists to treat
solid tumors. This is encouraging given PD-L1’s key role in
inhibiting the immune response and allowing tumor growth,” said
John Magnani, Vice President and Chief Scientific Officer of
GlycoMimetics and co-author of the poster. “The new preclinical
data show the scientific rationale for continuing clinical testing
of GMI-1359.”
GMI-1359 is now in a Phase 1 clinical trial. Previous research
on GMI-1359 has been shared at annual meetings of the American
Association for Cancer Research and the American Society of
Hematology.
Details of the poster at SITC, including session time and
location, are below:
Poster (All poster sessions are in the
Prince George’s Exhibition Hall in the Gaylord Convention
Center.)
Abstract 209—Combination of a
glycomimetic antagonist to E-selectin and CXCR4, GMI-1359, with an
anti-PD-L1 antibody attenuates regulatory T cell infiltration and
accelerates time to complete response in the murine CT26 tumor
model. Friday, Nov. 11, from 12:00-8:00 p.m.
The meeting abstracts are available at SITC’s website.
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company focused
on cancer and sickle cell disease. GlycoMimetics’ most advanced
drug candidate, rivipansel, a pan-selectin antagonist, is being
developed for the treatment of vaso-occlusive crisis in sickle cell
disease and is being evaluated in a Phase 3 clinical trial being
conducted by its strategic collaborator, Pfizer. GlycoMimetics’
wholly-owned drug candidate, GMI-1271, an E-selectin antagonist, is
being evaluated in an ongoing Phase 1/2 clinical trial as a
potential treatment for AML and in a Phase 1 clinical trial in
multiple myeloma. GlycoMimetics has also recently initiated a
clinical trial with a third drug candidate, GMI-1359, a combined
CXCR4 and E-selectin antagonist. GlycoMimetics is located in
Rockville, MD in the BioHealth Capital Region. Learn more at
www.glycomimetics.com.
Forward-Looking Statements
This press release contains forward-looking statements regarding
GlycoMimetics’ planned activities with respect to the clinical
development of its drug candidate GMI-1359. Actual results may
differ materially from those indicated by such forward-looking
statements as a result of various important factors, including the
availability and timing of data from ongoing clinical trials, the
uncertainties inherent in the initiation of future clinical trials,
whether interim results from a clinical trial will be predictive of
the final results of the trial or results of early clinical trials
will be indicative of the results of future trials, expectations
for regulatory approvals, availability of funding sufficient for
GlycoMimetics’ foreseeable and unforeseeable operating expenses and
capital expenditure requirements, other matters that could affect
the availability or commercial potential of GlycoMimetics’ drug
candidates and other factors discussed in the “Risk Factors”
section of GlycoMimetics’ Annual Report on Form 10-K that was filed
with the U.S. Securities and Exchange Commission on February 29,
2016, and other filings GlycoMimetics makes with the Securities and
Exchange Commission from time to time. In addition, the
forward-looking statements included in this press release represent
GlycoMimetics’ views as of the date hereof. GlycoMimetics
anticipates that subsequent events and developments may cause its
views to change. However, while GlycoMimetics may elect to update
these forward-looking statements at some point in the future,
GlycoMimetics specifically disclaims any obligation to do so,
except as may be required by law. These forward-looking statements
should not be relied upon as representing GlycoMimetics’ views as
of any date subsequent to the date hereof.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161108005663/en/
GlycoMimetics, Inc.Investor Contact:Shari Annes,
650-888-0902sannes@annesassociates.comorMedia Contact:Jamie
Lacey-Moreira, 410-299-3310jamielacey@presscommpr.com
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Mar 2024 to Apr 2024
GlycoMimetics (NASDAQ:GLYC)
Historical Stock Chart
From Apr 2023 to Apr 2024